ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation. ESSA Pharma’s rating score has improved by 40.1% from three months ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a 1-year consensus price target of $5.10 for the company, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 184 out of 265 based on the ratings given to related companies.

Several equities research analysts have recently issued reports on EPIX shares. Bloom Burton upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, January 18th. Zacks Investment Research upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research note on Tuesday, January 16th. Finally, ValuEngine upgraded shares of ESSA Pharma from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

Shares of ESSA Pharma (EPIX) traded down $0.01 during trading on Friday, hitting $0.19. 90,175 shares of the stock traded hands, compared to its average volume of 171,679. The firm has a market capitalization of $5.54, a P/E ratio of -0.68 and a beta of 2.00. The company has a debt-to-equity ratio of -0.84, a quick ratio of 1.26 and a current ratio of 0.62. ESSA Pharma has a twelve month low of $0.15 and a twelve month high of $3.59.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings data on Monday, December 11th. The company reported ($0.09) earnings per share (EPS) for the quarter. analysts anticipate that ESSA Pharma will post -0.29 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.

Leave a Reply